Key points are not available for this paper at this time.
More than 80% of the variance in the effect on relapses between trials is explained by the variance in MRI effects. Smaller and shorter phase II studies based on MRI lesion end points may give indications also on the effect of the treatment on relapse end points.
Sormani et al. (Sun,) studied this question.